CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Investing.com -- Novo Nordisk A/S (NYSE: NVO) stock dropped 2.1% premarket following news that Spain’s health ministry has requested clarification about the company’s obesity awareness campaign, which ...

Novo Nordisk A/S (NYSE:NVO) saw its stock decline 2.1% in premarket trading after Spain’s health ministry initiated an ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...